Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 12, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-019-0756-z
Keywords
Immunotherapy; Pediatric sarcoma; Osteosarcoma; Ewing's sarcoma; Rhabdomyosarcoma; Cancer vaccines; Adoptive cellular therapy; CAR T cell therapy; Checkpoint blockade
Categories
Funding
- National Institutes of Health [NCI F30-CA221345-01, NCI K08CA199224, NCI R01-CA195563-01, 1R01-CA175517-01]
- Rally Foundation
- US Department of Defense [W81XWH-17-1-0510]
- St. Baldrick's Foundation
- Department of Defense [W81XWH-10-1-0089]
- Hyundai Hope on Wheels
Ask authors/readers for more resources
While promising, immunotherapy has yet to be fully unlocked for the preponderance of cancers where conventional chemoradiation reigns. This remains particularly evident in pediatric sarcomas where standard of care has not appreciably changed in decades. Importantly, pediatric bone sarcomas, like osteosarcoma and Ewing's sarcoma, possess unique tumor microenvironments driven by distinct molecular features, as do rhabdomyosarcomas and soft tissue sarcomas. A better understanding of each malignancy's biology, heterogeneity, and tumor microenvironment may lend new insights toward immunotherapeutic targets in novel platform technologies for cancer vaccines and adoptive cellular therapy. These advances may pave the way toward new treatments requisite for pediatric sarcomas and patients in need of new therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available